RABEP1

Across TCGA pan-cancer cohorts, RABEP1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RABEP1 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RABEP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RABEP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and LGG are the cancer types where RABEP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.083	0.555	<.001	18	view →
UCEC	OS	Median	All	0.965	0.649	.018	14	view →
LGG	OS	Median	All	0.207	0.812	<.001	12	view →
COAD	OS	Median	II,III,IV	0.111	0.851	<.001	9	view →
PRAD	DFS	Median	All	0.486	0.936	<.001	6	view →
BLCA	DFS	Median	III,IV	0.249	0.575	.039	3	view →
SKCM	DFS	Median	All	0.834	0.209	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RABEP1–LIHC (DFS)

Open the LIHC breakdown →